Square Pharmaceuticals PLC. (DSE:SQURPHARMA)

Market Cap	194.31B -3.0%
Revenue (ttm)	83.53B +10.1%
Net Income	25.86B +10.0%
EPS	29.18 +10.0%
Shares Out	886.45M
PE Ratio	7.51
Forward PE	6.78
Dividend	12.00 (5.47%)
Ex-Dividend Date	Nov 17, 2025

Volume	245,124
Open	220.30
Previous Close	220.10
Day's Range	218.60 - 220.30
52-Week Range	198.00 - 236.00
Beta	0.09
Analysts	Strong Buy
Price Target	352.20 (+60.68%)
Earnings Date	Oct 22, 2026

About DSE:SQURPHARMA

Square Pharmaceuticals PLC., together with its subsidiaries, manufactures, markets, and distributes pharmaceutical products in Bangladesh and internationally. The company offers pharmaceutical products comprising alimentary preparations, amoebocides, analgesics, anthelmintics, anti-aphthous ulcer, anti-erectile dysfunction, anti-gout, anti-hyperkalemia, anti-osteoarthritis, anti-thyroid, anti-ulcerants, antiallergies, antianemics, antiasthma, antibiotics, antidiabetics, antifibrinolytics, antihemorrhoidals, antihistamines, antiosteoporotics, an...

• Industry: Pharmaceutical Preparations
• Founded: 1958
• Employees: 15,937
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SQURPHARMA

Financial Performance

In fiscal year 2025, DSE:SQURPHARMA's revenue was 76.29 billion, an increase of 8.83% compared to the previous year's 70.10 billion. Earnings were 23.97 billion, an increase of 14.54%.

Analyst Summary

According to 3 analysts, the average rating for SQURPHARMA stock is "Strong Buy." The 12-month stock price target is ৳352.20, which is an increase of 60.68% from the latest price.

Price Target

৳352.20

(60.68% upside)

Analyst Consensus: Strong Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 15, 2026

Data Sources Report a data error